These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35703246)

  • 61. Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.
    Isakova T; Ix JH; Sprague SM; Raphael KL; Fried L; Gassman JJ; Raj D; Cheung AK; Kusek JW; Flessner MF; Wolf M; Block GA
    J Am Soc Nephrol; 2015 Oct; 26(10):2328-39. PubMed ID: 25967123
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
    Weir MR
    Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Phosphate metabolism and iron deficiency].
    Yokoyama K
    Clin Calcium; 2016 Feb; 26(2):241-9. PubMed ID: 26813504
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
    Zhao SJ; Wang ZX; Chen L; Wang FX; Kong LD
    Ann Palliat Med; 2022 Apr; 11(4):1264-1277. PubMed ID: 34775773
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Fibroblast growth factor 23 actions in inflammation: a key factor in CKD outcomes.
    Rossaint J; Unruh M; Zarbock A
    Nephrol Dial Transplant; 2017 Sep; 32(9):1448-1453. PubMed ID: 27659127
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia.
    Landau D; London L; Bandach I; Segev Y
    PLoS One; 2018; 13(5):e0196684. PubMed ID: 29738538
    [TBL] [Abstract][Full Text] [Related]  

  • 67. High Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4.
    Tsai MH; Leu JG; Fang YW; Liou HH
    Medicine (Baltimore); 2016 Mar; 95(11):e3049. PubMed ID: 26986127
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure.
    van Breda F; Emans ME; van der Putten K; Braam B; van Ittersum FJ; Kraaijenhagen RJ; de Borst MH; Vervloet M; Gaillard CA
    PLoS One; 2015; 10(6):e0128994. PubMed ID: 26079688
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Roxadustat: Do we know all the answers?
    Li QY; Xiong QW; Yao X; Liu F; Tang X; Fu H; Tong T; Mao J; Peng WX
    Biomol Biomed; 2023 May; 23(3):354-363. PubMed ID: 36724056
    [TBL] [Abstract][Full Text] [Related]  

  • 70. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.
    Edmonston D; Wolf M
    Nat Rev Nephrol; 2020 Jan; 16(1):7-19. PubMed ID: 31519999
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Oral Versus Intravenous Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients on Maintenance Hemodialysis-Effect on Fibroblast Growth Factor-23 Metabolism.
    Fukao W; Hasuike Y; Yamakawa T; Toyoda K; Aichi M; Masachika S; Kantou M; Takahishi SI; Iwasaki T; Yahiro M; Nanami M; Nagasawa Y; Kuragano T; Nakanishi T
    J Ren Nutr; 2018 Jul; 28(4):270-277. PubMed ID: 29703633
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Fibroblast growth factor 23 (FGF23) induces ventricular arrhythmias and prolongs QTc interval in mice in an FGF receptor 4-dependent manner.
    Graves JM; Vallejo JA; Hamill CS; Wang D; Ahuja R; Patel S; Faul C; Wacker MJ
    Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2283-H2294. PubMed ID: 33929896
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Therapeutics of managing reduced red cell mass associated with chronic kidney disease - Is there a case for earlier intervention?
    Elliott J
    J Vet Pharmacol Ther; 2023 May; 46(3):145-157. PubMed ID: 37036059
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23.
    Navarro-García JA; Salguero-Bodes R; González-Lafuente L; Martín-Nunes L; Rodríguez-Sánchez E; Bada-Bosch T; Hernández E; Mérida-Herrero E; Praga M; Solís J; Arribas F; Bueno H; Kuro-O M; Fernández-Velasco M; Ruilope LM; Delgado C; Ruiz-Hurtado G
    BMC Med; 2022 Jan; 20(1):14. PubMed ID: 35042527
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation.
    Wish JB; Eckardt KU; Kovesdy CP; Fishbane S; Spinowitz BS; Berns JS
    Am J Kidney Dis; 2021 Nov; 78(5):709-718. PubMed ID: 34332007
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Circulating Fibroblast Growth Factor-23 Levels are Associated with an Increased Risk of Anemia Development in Patients with Nondialysis Chronic Kidney Disease.
    Nam KH; Kim H; An SY; Lee M; Cha MU; Park JT; Yoo TH; Lee KB; Kim YH; Sung SA; Lee J; Kang SW; Choi KH; Ahn C; Han SH
    Sci Rep; 2018 May; 8(1):7294. PubMed ID: 29740119
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.
    Flamme I; Oehme F; Ellinghaus P; Jeske M; Keldenich J; Thuss U
    PLoS One; 2014; 9(11):e111838. PubMed ID: 25392999
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis.
    Fukuta H; Hagiwara H; Kamiya T
    PLoS One; 2022; 17(9):e0275311. PubMed ID: 36170343
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Regulation and Effects of FGF23 in Chronic Kidney Disease.
    Musgrove J; Wolf M
    Annu Rev Physiol; 2020 Feb; 82():365-390. PubMed ID: 31743079
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Epoetin Beta and C-Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease.
    Eisenga MF; Emans ME; van der Putten K; Cramer MJ; Diepenbroek A; Velthuis BK; Doevendans PA; Verhaar MC; Joles JA; Bakker SJL; Nolte IM; Braam B; Gaillard CAJM
    J Am Heart Assoc; 2019 Aug; 8(16):e011130. PubMed ID: 31423921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.